(4-(2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzamido)-2-oxo-1l4,2l5-pyridin-1-yl)methyldihydrogenphosphate manufacturers
- VX-150
-
- $115.00 / 1mg
-
2024-11-19
- CAS:1793080-72-4
- Min. Order:
- Purity: 95.06%
- Supply Ability: 10g
|
| (4-(2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzamido)-2-oxo-1l4,2l5-pyridin-1-yl)methyldihydrogenphosphate Basic information |
Product Name: | (4-(2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzamido)-2-oxo-1l4,2l5-pyridin-1-yl)methyldihydrogenphosphate | Synonyms: | (4-(2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzamido)-2-oxo-1l4,2l5-pyridin-1-yl)methyldihydrogenphosphate;EOS-62073;(4-(2-(4-fluoro-2-methylphenoxy)
-4-(trifluoromethyl)benzamido)
-2-oxopyridin-1(2H)-yl)methyl
dihydrogen phosphate;Benzamide, N-[1,2-dihydro-2-oxo-1-[(phosphonooxy)methyl]-4-pyridinyl]-2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)-;VX-150;Na+ channels,VX-150,indications,Inhibitor,Na channels,orally,inhibit,pain,VX 150,VX150,Sodium Channel;Sorafenib Impurity 86;Pramipexole Impurity 66-d5 Dihydrochloride | CAS: | 1793080-72-4 | MF: | C21H17F4N2O7P | MW: | 516.34 | EINECS: | | Product Categories: | | Mol File: | 1793080-72-4.mol |  |
| (4-(2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzamido)-2-oxo-1l4,2l5-pyridin-1-yl)methyldihydrogenphosphate Chemical Properties |
density | 1.59±0.1 g/cm3(Predicted) | storage temp. | Store at -20°C | solubility | DMSO : 125 mg/mL (242.09 mM; Need ultrasonic) | form | Solid | pka | 1.72±0.10(Predicted) | color | White to off-white |
| (4-(2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzamido)-2-oxo-1l4,2l5-pyridin-1-yl)methyldihydrogenphosphate Usage And Synthesis |
Uses | VX-150 is an orally active, highly selective NaV1.8 inhibitor. VX-150 has the potential for various pain indications research[1]. | IC 50 | Nav1.8 | References | [1] Hemme J Hijma, et al. A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Pharmacodynamic Effects of VX-150, a Highly Selective NaV1.8 Inhibitor, in Healthy Male Adults. Pain Med. 2021 Aug 6;22(8):1814-1826. DOI:10.1093/pm/pnab032 |
| (4-(2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzamido)-2-oxo-1l4,2l5-pyridin-1-yl)methyldihydrogenphosphate Preparation Products And Raw materials |
|